Benzinga
Benzinga
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Benzinga
lundi, octobre 19
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
ORIC Pharmaceuticals Inc
ORIC
NASDAQ
Liste de surveillance
Get Report
Trade with Public
Get Report
Trade with Public
$12.35
-0.42
-3.29%
Dern. MÀJ: Oct 16, 5:05 PM
$12.50
-0.27
-2.11%
Get Report
Aperçu
Actualités
Prévisions de résultats
Événements
Objectifs de cours
Données financières
Sentiment
Actionnariat
Comparer
Options
Rapport sur les stocks
Privacy Manager
ORIC Pharmaceuticals Financials
ORIC Pharmaceuticals (ORIC) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
ORIC Pharmaceuticals Q2 EPS $(0.38) Misses $(0.36) Estimate
ORIC Pharmaceuticals (NASDAQ:ORIC) reported quarterly losses of $(0.38) per share which missed the analyst consensus estimate of $(0.36) by 5.56 percent. This is a 19.15 percent increase over losses of $(0.47) per share
Benzinga Newsdesk
PRO
ORIC Pharmaceuticals Q1 EPS $(0.34) Misses $(0.32) Estimate
Benzinga Newsdesk
PRO
ORIC Pharmaceuticals Q4 EPS $(0.30) Beats $(0.37) Estimate
ORIC Pharmaceuticals (NASDAQ:ORIC) reported quarterly losses of $(0.30) per share which beat the analyst consensus estimate of $(0.37) by 18.7 percent. This is a 41.18 percent increase over losses of $(0.51) per share
Benzinga Newsdesk
PRO
ORIC Pharmaceuticals Q3 EPS $(0.33) Beats $(0.42) Estimate
ORIC Pharmaceuticals (NASDAQ:ORIC) reported quarterly losses of $(0.33) per share which beat the analyst consensus estimate of $(0.42) by 21.99 percent. This is a 32.65 percent increase over losses of $(0.49) per share
Benzinga Newsdesk
PRO
ORIC Pharmaceuticals Q2 EPS $(0.47) Misses $(0.44) Estimate
Benzinga Newsdesk
Crude Oil Falls Over 1%; Best Buy Reports Downbeat Results
Avi Kapoor
